I completely agree. A BP is needed to fast track the commercialisation and expansion of targeted indications (100s +) when there's a medical through like NNZ2561. This is in the best interests of all stakeholders involved including shareholders and patients. It's also very likely that the existing management will be retained and highly remunerated under the new ownership given their intimate knowledge of the compound.
Share Price, page-8543
-
- There are more pages in this discussion • 3,308 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.56 |
Change
0.225(1.69%) |
Mkt cap ! $1.739B | |||
| Open | High | Low | Value | Volume |
| $13.49 | $13.61 | $13.30 | $3.079M | 228.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 350 | $13.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.56 | 1186 | 21 |
View Market Depth
| Last trade - 14.57pm 12/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |